“We are delighted that Bredis is Checkmate’s first direct investment in Korea, sourced through our new international office based in Seoul, and our first collaborative investment with our trusted partner, KAIST,” stated Jay Ryu, Managing Director of Checkmate. We expect that early detection combined with integrated disease treatment and management will offer new tools that can begin to turn the tide against devastating diseases such as Alzheimer’s and other forms of dementia,” commented Checkmate CEO Tom Paschall. “We believe that, in light of recent advancements in the treatment and control of neurodegenerative diseases, including humanized monoclonal antibodies targeting amyloid beta plaques and Treg cell therapy targeting neuroinflammation, Bredis has perfectly timed the launch of its high-sensitivity blood-based biomarkers for neurodegenerative diseases. As a startup team from KAIST, we believe Bredis will become a promising biomarker-based diagnostics enterprise that grows rapidly through the KAIST startup ecosystem,” commented Henry Chung, CEO of KAIST Ventures. This investment will help accelerate Bredis’ commercial growth and the buildout of its laboratory facilities. Bredis’ technology uses AI-driven data analytics and a blood -based approach to enable the early diagnosis of Alzheimer’s disease. “Using its proprietary biomarker analysis technology, Bredis solves many well-known, chronic problems in the neurodegenerative diagnostics market. The Bredis blood-based biomarker is derived from many years of clinical research conducted by Bredis’ founders. Bredis’ ambition is to provide an integrated solution for the diagnosis, prevention, treatment, and management of dementia by utilizing its state-of-the-art biomarker tests and proprietary artificial intelligence (AI) data analytics models.
Bredis has developed a proprietary platform that accurately diagnoses Alzheimer’s disease with a simple blood test, predicts prognosis of future health outcomes, and supports disease management. The transaction is an extension of the partnership and collaboration previously announced between KAIST and Checkmate last year in which a KAIST-Checkmate consortium became a program operator in Korea’s Tech Incubator Program for Startups (“ TIPS”).įounded in February 2023, Bredis is already providing its ultra-sensitive biomarker detection services to leading university hospitals and research institutes in Korea and is preparing product approvals for in-vitro diagnostic medical devices. KAIST led the redeemable convertible preferred stock investment and Checkmate was the sole non-Korean investor. Bredis is a leading neurodegenerative diagnostics company that has pioneered its patent-protected, digital ELISA technology that is 10,000 times more sensitive than existing blood test technology. SEOUL, Korea and PASADENA, Calif., (GLOBE NEWSWIRE) - KAIST Venture Investment Holdings (“ KAIST” or “ KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“ Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“ Bredis”). Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Koreaįurther Announcement of Bredis’ Agreements with Major University Hospitals
0 kommentar(er)
